Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

An analyst tracking the stock made a drastic change to his price target. The latest biotech stock to explode in price, Nektar ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...